Grifols S.A. (GRFS) 41.50 $GRFS
Grifols Relies On Expansion Abroad To Fuel Growth
at Investor's Business Daily - Fri May 09, 5:28PM CDT
IBD 50 stock Grifols (GRFS) has relied on global expansion to escape economic troubles in its home country of Spain. The company became among the world's biggest makers of plasma products two years ago when it purchased North Carolina-based Talecris...
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
New drug sales help boost Novartis Q1 profit
By JOHN HEILPRIN - AP - Thu Apr 24, 11:46AM CDT
GENEVA (AP) — Strong new drug sales and higher operating income helped Swiss pharmaceutical firm Novartis AG report a 24 percent rise in first-quarter profit.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Grifols Celebrates World Hemophilia Day with Donation of Coagulation Medicines to the World Federation of Hemophilia
PR Newswire - Thu Apr 17, 7:47AM CDT
Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a decade - and this unprecedented product donation represents its largest commitment to date. According to the WFH, this donation of blood clotting factor products will secure an average of 40,000 doses to treat approximately 10,000 patients in developing countries worldwide through 2017, where access to adequate treatment is often lacking or absent.
Stocks Fade From Fresh Session High
at Investor's Business Daily - Wed Apr 16, 12:55PM CDT
Stocks eased Wednesday afternoon after briefly pushing to new session highs on reassuring comments by Fed Chairwoman Janet Yellen. The Nasdaq and the Dow Jones industrial average were each up 0.6%, while the S&P 500 rose 0.5%. Volume continued to...
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Facebook, Arris, Grifols Initiate New Bases
at Investor's Business Daily - Fri Apr 11, 5:35PM CDT
With the stock market in a correction, the investor should emphasize defense. This means keeping cash in the portfolio, cutting losses on any stocks that are falling fast, and taking at least some profits on stocks that trigger key sell signals....
PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day
Global Critical Care Market 2013-2019
M2 - Fri Apr 11, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prjqh7/critical_care) has announced the addition of the "Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific" report to their offering. The overall critical care therapeutics market was worth $2.3 billion in 2012, having grown in size at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increased demand for and cost of albumin, as well as the approval and launch of new products. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets, as well as for leading therapeutic segments. The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market. The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the EU and is expected to be launched in the US later this year), the expanded indication for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in the Asia-Pacific region. Stagnant innovations, a low prevalence rate and the consequent limited availability of patients are some of the factors impeding the growth of the critical care market. Key Topics Covered: - Tables & Figures - Introduction - Critical Care Market to 2019 - Global Overview - Critical Care Market to 2019 - Geographical Landscape - Critical Care Market to 2019 - Albumin Market - Critical Care Market to 2019 - Antithrombin Concentrate Market - Critical Care Market to 2019 - Fibrinogen Concentrate Market - Critical Care Market to 2019 - Prothrombin Complex Concentrate Market - Critical Care Market to 2019 - Factor XIII Concentrate Market - Critical Care Market to 2019 - Research and Development Product Pipeline - Critical Care Market to 2019 - Competitive Landscape - Critical Care Market to 2019 - Strategic Consolidation - Critical Care Market to 2019 - Appendix Companies Mentioned - Baxter International Incorporated - Bio Products Laboratory Limited - Biotest - China Biologic Products, Incorporated - CSL Limited - Grifols, SA - Hualan Biological Engineering, Incorporated - Kedrion SpA - aboratoire Fran?ais de Fractionnement et de Biotechnologies - Octapharma AG - Sanquin Blood Supply Foundation - Shanghai RAAS Blood Products Company, Limited For more information visit http://www.researchandmarkets.com/research/pr...tical_care
Fluor-Designed and Built Plasma Fractionation Facility Awarded ISPE 2014 Facility of the Year for Project Execution
Business Wire - Thu Apr 10, 3:37PM CDT
Fluor Corporation (NYSE: FLR) announced today that Grifols' North Fractionation Facility in Clayton, N.C., was named the International Society for Pharmaceutical Engineering (ISPE) 2014 Facility of the Year for Project Execution.
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Stocks Weaken In Late Trade; Questcor Pares Gains
at Investor's Business Daily - Mon Apr 07, 1:57PM CDT
Stocks continued to worsen in late trading Monday and were on pace for a third straight loss. The Nasdaq slumped 1.7% to a two-month low. The S&P 500 dropped 1.2%, putting it near its 50-day line. Meanwhile, the Dow Jones industrial average lost 1%....
Major Averages Face More Selling, Biotechs Rally Back
at Investor's Business Daily - Mon Apr 07, 11:01AM CDT
Stocks were under pressure and near session lows about two hours into Monday's session. Biotechs bucked the trend, rallying back after recent weakness. The Dow Jones industrial average lost 0.6%, while the Nasdaq and S&P 500 fell 0.5%. Nasdaq volume...
Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014
PR Newswire - Fri Apr 04, 10:54AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 4, 2014. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2013.
Salix Among Stocks Getting Support At 10-Week Line
at Investor's Business Daily - Thu Apr 03, 5:13PM CDT
A number of leading stocks in Your Weekly Review are in a secondary buy range amid the market's renewed uptrend. Stocks in the highly rated Medical-Ethical Drugs industry again led this week's list, which expanded to 109 members after shrinking to...
Stocks Hold Near Highs; Heartland Keeps On Trucking
at Investor's Business Daily - Mon Mar 31, 1:57PM CDT
The major averages were holding near session highs late Monday afternoon, buoyed by dovish comments from Federal Reserve chief Janet Yellen. The Nasdaq was up 1.2%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. However, volume was...
Concise Analysis of the International Cell Surface Markers Market - Forecasts to 2018
M2 - Mon Mar 31, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkhjg7/cell_surface) has announced the addition of the "Concise Analysis of the International Cell Surface Markers Market - Forecasts to 2018" report to their offering. Cell surface markers are unique to cell types and have vital functional role in immunology. These are generally antigens or molecules present within the plasma membrane of the cell. Such markers serve as the prime component in identification and categorization of cells such as lymphocytes, macrophages, monocytes, tumor cells and other cells majorly related to immunology. Cell surface marker analysis is performed through the use of technologies namely, flow cytometry and hematology analyzers and can be carried out on various samples such as lymph nodes, blood, bone marrow and other tissues. Such analysis may allow simplification of disease diagnosis and identification, sample preparation and drug discovery. Identification of specific types of molecules through cell surface marker analysis helps in efficient disease diagnosis and thereby assists in determination of disease treatment and drugs. Cell surface markers analysis enables the quantification of the scope of new drugs reaching the intended target and are also responsible for achieving the clinical outcomes by altering the proposed pathophysiological mechanisms. Disease diagnosis by detection or use of cell surface markers has been beneficial and critical in developing innovative and reliable indicators with high specificity for the diagnosis and prognosis of different types of diseases, majorly cancer. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cell Surface Markers Market, by Instruments and Reagents Chapter 5 Global Cell Surface Markers Market, by Applications Chapter 6 Global Cell Surface Markers Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - BD Biosciences - Beckman Coulter, Inc - Bio-Rad Laboratories, Inc - F Hoffmann-La Roche Ltd - Grifols SA - Immucor, Inc - Janssen Diagnostics, Inc - Nihon Kohden Corporation - Siemens Healthcare - Sysmex Corporation - Thermo Fischer Scientific, Inc For more information visit http://www.researchandmarkets.com/research/xk...ll_surface
Grifols Relies On Expansion Abroad To Fuel Growth
at Investor's Business Daily - Fri May 09, 5:28PM CDT
IBD 50 stock Grifols (GRFS) has relied on global expansion to escape economic troubles in its home country of Spain. The company became among the world's biggest makers of plasma products two years ago when it purchased North Carolina-based Talecris...
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
New drug sales help boost Novartis Q1 profit
By JOHN HEILPRIN - AP - Thu Apr 24, 11:46AM CDT
GENEVA (AP) — Strong new drug sales and higher operating income helped Swiss pharmaceutical firm Novartis AG report a 24 percent rise in first-quarter profit.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Grifols Celebrates World Hemophilia Day with Donation of Coagulation Medicines to the World Federation of Hemophilia
PR Newswire - Thu Apr 17, 7:47AM CDT
Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a decade - and this unprecedented product donation represents its largest commitment to date. According to the WFH, this donation of blood clotting factor products will secure an average of 40,000 doses to treat approximately 10,000 patients in developing countries worldwide through 2017, where access to adequate treatment is often lacking or absent.
Stocks Fade From Fresh Session High
at Investor's Business Daily - Wed Apr 16, 12:55PM CDT
Stocks eased Wednesday afternoon after briefly pushing to new session highs on reassuring comments by Fed Chairwoman Janet Yellen. The Nasdaq and the Dow Jones industrial average were each up 0.6%, while the S&P 500 rose 0.5%. Volume continued to...
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Facebook, Arris, Grifols Initiate New Bases
at Investor's Business Daily - Fri Apr 11, 5:35PM CDT
With the stock market in a correction, the investor should emphasize defense. This means keeping cash in the portfolio, cutting losses on any stocks that are falling fast, and taking at least some profits on stocks that trigger key sell signals....
PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day
Global Critical Care Market 2013-2019
M2 - Fri Apr 11, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prjqh7/critical_care) has announced the addition of the "Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific" report to their offering. The overall critical care therapeutics market was worth $2.3 billion in 2012, having grown in size at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increased demand for and cost of albumin, as well as the approval and launch of new products. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets, as well as for leading therapeutic segments. The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market. The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the EU and is expected to be launched in the US later this year), the expanded indication for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in the Asia-Pacific region. Stagnant innovations, a low prevalence rate and the consequent limited availability of patients are some of the factors impeding the growth of the critical care market. Key Topics Covered: - Tables & Figures - Introduction - Critical Care Market to 2019 - Global Overview - Critical Care Market to 2019 - Geographical Landscape - Critical Care Market to 2019 - Albumin Market - Critical Care Market to 2019 - Antithrombin Concentrate Market - Critical Care Market to 2019 - Fibrinogen Concentrate Market - Critical Care Market to 2019 - Prothrombin Complex Concentrate Market - Critical Care Market to 2019 - Factor XIII Concentrate Market - Critical Care Market to 2019 - Research and Development Product Pipeline - Critical Care Market to 2019 - Competitive Landscape - Critical Care Market to 2019 - Strategic Consolidation - Critical Care Market to 2019 - Appendix Companies Mentioned - Baxter International Incorporated - Bio Products Laboratory Limited - Biotest - China Biologic Products, Incorporated - CSL Limited - Grifols, SA - Hualan Biological Engineering, Incorporated - Kedrion SpA - aboratoire Fran?ais de Fractionnement et de Biotechnologies - Octapharma AG - Sanquin Blood Supply Foundation - Shanghai RAAS Blood Products Company, Limited For more information visit http://www.researchandmarkets.com/research/pr...tical_care
Fluor-Designed and Built Plasma Fractionation Facility Awarded ISPE 2014 Facility of the Year for Project Execution
Business Wire - Thu Apr 10, 3:37PM CDT
Fluor Corporation (NYSE: FLR) announced today that Grifols' North Fractionation Facility in Clayton, N.C., was named the International Society for Pharmaceutical Engineering (ISPE) 2014 Facility of the Year for Project Execution.
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Stocks Weaken In Late Trade; Questcor Pares Gains
at Investor's Business Daily - Mon Apr 07, 1:57PM CDT
Stocks continued to worsen in late trading Monday and were on pace for a third straight loss. The Nasdaq slumped 1.7% to a two-month low. The S&P 500 dropped 1.2%, putting it near its 50-day line. Meanwhile, the Dow Jones industrial average lost 1%....
Major Averages Face More Selling, Biotechs Rally Back
at Investor's Business Daily - Mon Apr 07, 11:01AM CDT
Stocks were under pressure and near session lows about two hours into Monday's session. Biotechs bucked the trend, rallying back after recent weakness. The Dow Jones industrial average lost 0.6%, while the Nasdaq and S&P 500 fell 0.5%. Nasdaq volume...
Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014
PR Newswire - Fri Apr 04, 10:54AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 4, 2014. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2013. Salix Among Stocks Getting Support At 10-Week Line
at Investor's Business Daily - Thu Apr 03, 5:13PM CDT
A number of leading stocks in Your Weekly Review are in a secondary buy range amid the market's renewed uptrend. Stocks in the highly rated Medical-Ethical Drugs industry again led this week's list, which expanded to 109 members after shrinking to...
Stocks Hold Near Highs; Heartland Keeps On Trucking
at Investor's Business Daily - Mon Mar 31, 1:57PM CDT
The major averages were holding near session highs late Monday afternoon, buoyed by dovish comments from Federal Reserve chief Janet Yellen. The Nasdaq was up 1.2%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. However, volume was...
Concise Analysis of the International Cell Surface Markers Market - Forecasts to 2018
M2 - Mon Mar 31, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xkhjg7/cell_surface) has announced the addition of the "Concise Analysis of the International Cell Surface Markers Market - Forecasts to 2018" report to their offering. Cell surface markers are unique to cell types and have vital functional role in immunology. These are generally antigens or molecules present within the plasma membrane of the cell. Such markers serve as the prime component in identification and categorization of cells such as lymphocytes, macrophages, monocytes, tumor cells and other cells majorly related to immunology. Cell surface marker analysis is performed through the use of technologies namely, flow cytometry and hematology analyzers and can be carried out on various samples such as lymph nodes, blood, bone marrow and other tissues. Such analysis may allow simplification of disease diagnosis and identification, sample preparation and drug discovery. Identification of specific types of molecules through cell surface marker analysis helps in efficient disease diagnosis and thereby assists in determination of disease treatment and drugs. Cell surface markers analysis enables the quantification of the scope of new drugs reaching the intended target and are also responsible for achieving the clinical outcomes by altering the proposed pathophysiological mechanisms. Disease diagnosis by detection or use of cell surface markers has been beneficial and critical in developing innovative and reliable indicators with high specificity for the diagnosis and prognosis of different types of diseases, majorly cancer. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cell Surface Markers Market, by Instruments and Reagents Chapter 5 Global Cell Surface Markers Market, by Applications Chapter 6 Global Cell Surface Markers Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - BD Biosciences - Beckman Coulter, Inc - Bio-Rad Laboratories, Inc - F Hoffmann-La Roche Ltd - Grifols SA - Immucor, Inc - Janssen Diagnostics, Inc - Nihon Kohden Corporation - Siemens Healthcare - Sysmex Corporation - Thermo Fischer Scientific, Inc For more information visit http://www.researchandmarkets.com/research/xk...ll_surface
